Medicenna Therapeutics Income Statement

Financials in millions CAD. Fiscal year is April - March.

Millions CAD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2016 - 2020
Period Ending	Jun '25 Jun 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	2016 - 2020
Selling, General & Admin	6.01	5.96	7.87	7	7.76	6.53	Upgrade
Research & Development	15.87	14.44	10.8	9.3	14.72	10.87	Upgrade
Operating Expenses	21.88	20.41	18.67	16.3	22.47	17.4	Upgrade
Operating Income	-21.88	-20.41	-18.67	-16.3	-22.47	-17.4	Upgrade
Interest & Investment Income	1.22	1.35	1.2	0.91	0.07	0.31	Upgrade
Currency Exchange Gain (Loss)	-0.11	0.9	-0.07	1.65	-0.17	-0.21	Upgrade
Other Non Operating Income (Expenses)	7.67	6.35	-7.92	3.7	-	-	Upgrade
EBT Excluding Unusual Items	-13.1	-11.81	-25.47	-10.05	-22.58	-17.29	Upgrade
Pretax Income	-13.1	-11.81	-25.47	-10.05	-22.58	-17.29	Upgrade
Net Income	-13.1	-11.81	-25.47	-10.05	-22.58	-17.29	Upgrade
Net Income to Common	-13.1	-11.81	-25.47	-10.05	-22.58	-17.29	Upgrade
Shares Outstanding (Basic)	79	77	70	65	54	50	Upgrade
Shares Outstanding (Diluted)	79	77	70	65	54	50	Upgrade
Shares Change (YoY)	11.70%	10.10%	7.57%	19.25%	9.31%	55.68%	Upgrade
EPS (Basic)	-0.17	-0.15	-0.37	-0.16	-0.42	-0.35	Upgrade
EPS (Diluted)	-0.17	-0.15	-0.37	-0.16	-0.42	-0.35	Upgrade
Free Cash Flow	-17.71	-16.53	-16.26	-12.66	-23.58	-15.31	Upgrade
Free Cash Flow Per Share	-0.22	-0.22	-0.23	-0.20	-0.43	-0.31	Upgrade
EBITDA	-21.84	-20.39	-18.67	-16.3	-22.44	-17.36	Upgrade
D&A For EBITDA	0.03	0.02	0	0	0.04	0.04	Upgrade
EBIT	-21.88	-20.41	-18.67	-16.3	-22.47	-17.4	Upgrade

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.